Stifel maintains Halliburton stock Buy rating, $42 target
Stifel analysts maintained a Buy rating and a $42.00 price target for Halliburton (NYSE:HAL), following the company's fourth-quarter earnings report for 2024. With a current P/E ratio of 10.3x and an ...
Cytokinetics started at buy by Stifel, aficamten highlighted
Stifel has initiated coverage of Cytokinetics (CYTK) with a buy rating, citing its drug aficamten, valuation and upcoming ...
Edgewise rated as a new Hold at Stifel on a balanced risk-reward setup
Edgewise Therapeutics (EWTX) stock traded flat as Stifel launched its coverage with a Hold recommendation, indicating a ...
Cytokinetics initiated with a Buy at Stifel
Stifel initiated coverage of Cytokinetics (CYTK) with a Buy rating and $80 price target Cytokinetics “is an out-of-favor stock” following the ...
Stifel maintains Buy on Evolus, price target steady at $25
Stifel analysts maintained a Buy rating on Evolus (NASDAQ:EOLS) with a steady price target of $25.00. The firm's positive ...